RiboBio Launches IPO with $100 Million Cornerstone Investment Commitment

Dec 31, 2025 10:18 CST Updated 10:18

Ribo Life Science

Small Nucleic Acid Drug Developer

On December 31, Ribo Life Science-B issued an announcement,The company plans to offer 27,487,400 H shares globally between December 31, 2025, and January 6, 2026., of which 10% will be for the Hong Kong offering and 90% for the international offering, with an over-allotment option of 15%. The issue price per share is HKD 57.97, and H shares will be traded in board lots of 200 H shares each. It is expected that the H shares will commence trading on the Stock Exchange at 9:00 a.m. on January 9, 2026 (Friday).

Ribo Life Science entered into cornerstone investment agreements with cornerstone investors Arc Avenue, Bright Stone, China Asset Management, Da Cheng International and Da Cheng Fund, Erik Selin Fastigheter AB, Himension Fund, IvyRock, Mingxin Growth Ventures, Springs Capital (Hong Kong), Taikang Life Insurance and Shibe Nengxin, Natural Shibe, as well as Huatai Capital Investment Limited (regarding Huatai OTC swaps). The cornerstone investors have agreed.To subscribe or cause its designated entity to subscribe for the relevant number of placement shares purchasable with a total amount of approximately 100 million US dollars at the placement price, subject to the satisfaction of certain conditions.。

According to the prospectus, Ribo Life Science was founded in 2007 as a biopharmaceutical company engaged in the research and development of small nucleic acid drugs, with a particular focus on siRNA therapies.A core product for the treatment of thrombotic diseasesRBD4059 (siRNA Targeting FXI)In the R&D pipeline, there are seven self-developed drug assets in clinical trial stages, covering seven indications related to cardiovascular, metabolic, kidney, and liver diseases, four of which are in Phase 2 clinical trials.Product.

According to the prospectus, in terms of finance, for the years ended December 31, 2023 and 2024, and for the six months ended June 30, 2024 and 2025, Ribo Life Science's research and development expenditures were RMB 316 million, RMB 280 million, RMB 135 million, and RMB 129 million, respectively. The company expects its research and development expenditures to increase with future business growth.

For the year ended December 31, 2024, and the six months ended June 30, 2024, and June 30, 2025, Ribo Life Science generated revenues of RMB 143 million, RMB 66.3 million, and RMB 104 million, respectively, a significant portion of which came from the company's licensing and collaboration agreements.

As of the latest practicable date, the CompanyHas not yet generated any revenue from the sale of commercial products, and continue to incur substantial research and development expenses along with other expenses related to ongoing operations. For the years ended December 31, 2023 and 2024, and for the six months ended June 30, 2024 and 2025, the company's net losses were RMB 437 million, RMB 282 million, RMB 142 million, and RMB 97.8 million, respectively.

Prospectus link:

https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1231/2025123100038_c.pdf

End

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly attributed. This official account welcomes sharing in friend circles or large groups.Unauthorized reproduction by media or institutions in any form to other platforms is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more

Previous Review

Latest! Top 30 Global Pharmaceutical Giants by Market Value

Review of Innovative Drug Development: A New Starting Point After the Bubble Burst

BCG 2025 Industry Review: Innovative Drugs and China's Accelerated Rise